<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">AMITRIPTYLINE HYDROCHLORIDE</span><br/>(a-mee-trip'ti-leen)<br/><span class="topboxtradename">Amitril, </span><span class="topboxtradename">Apo-Amitriptyline <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Emitrip, </span><span class="topboxtradename">Endep, </span><span class="topboxtradename">Enovil, </span><span class="topboxtradename">Levate <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Meravil, </span><span class="topboxtradename">Novotriptyn <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">SK-Amitriptyline<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">psychotherapeutic</span>; <span class="classification">tricyclic antidepressant</span><br/><b>Prototype: </b>Imipramine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets; 10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Among the most active of the tricyclic antidepressants (TCAs) in inhibition of serotonin uptake from synaptic gap; also inhibits
         norepinephrine reuptake to a moderate degree. Restoration of the levels of these neurotransmitters is a proposed mechanism
         of antidepressant action.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Interference with the reuptake of serotonin and norepinephrine results in the antidepressant activity of amitriptyline.</p>
<h1><a name="uses">Uses</a></h1>
<p>Endogenous depression.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Prophylaxis for cluster, migraine, and chronic tension headaches; intractable pain, peptic ulcer disease, to increase muscle
         strength in myotonic dystrophy, to treat pathologic weeping and laughing secondary to forebrain disease, for eating disorders
         associated with depression (anorexia or bulimia), and as sedative for nondepressed patients.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Acute recovery period after MI, history of seizure disorders, pregnancy (category C), lactation, children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Prostatic hypertrophy, history of urinary retention or obstruction; angle-closure glaucoma; diabetes mellitus; hyperthyroidism;
         patient with cardiovascular, hepatic, or renal dysfunction; patient with suicidal tendency, electroshock therapy; elective
         surgery; schizophrenia; respiratory disorders; older adults, adolescents.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Antidepressant</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 75100 mg/d, may gradually increase to 150300 mg/d (use lower doses in outpatients) <span class="rdroute">IM</span> 2030 mg q.i.d. until patient can take PO<br/><span class="rdage">Adolescent:</span> <span class="rdroute">PO</span> 2550 mg/d in divided doses, may gradually increase to 100 mg/d (max: 200 mg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 1025 mg h.s., may gradually increase to 25150 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with or immediately after food to reduce possibility of GI irritation. Tablet may be crushed if patient is unable to
            take it whole; administer with food or fluid.
         </li>
<li>Give increased doses preferably in late afternoon or at bedtime due to sedative action that precedes antidepressant effect.</li>
<li>Give as single dose at bedtime to promote sleep or for patients with dizziness or when daytime sedation interferes with work
            productivity.
         </li>
<li>Note that dose is usually tapered over 2 wk at discontinuation to prevent withdrawal symptoms (headache, nausea, malaise,
            musculoskeletal pain, panic attack, weakness).
         </li>
</ul><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>Reserve IM injections for patients unable or unwilling to take oral drug.</li>
<li>Inject deep IM into a large muscle.</li>
<li>Store drug at 15°30° C (59°86° F) and protect from light unless otherwise directed by manufacturer.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Drowsiness, sedation, dizziness</span>, nervousness, restlessness, fatigue, headache, insomnia, abnormal movements (extrapyramidal symptoms), seizures. <span class="typehead">CV:</span>
<span class="speceff-common">Orthostatic hypotension</span>, tachycardia, palpitation, ECG changes. <span class="typehead">Special Senses:</span> Blurred vision, mydriasis. <span class="typehead">GI:</span>
<span class="speceff-common">Dry mouth</span>, increased appetite especially for sweets, <span class="speceff-common">constipation,</span> weight gain, sour or metallic taste, nausea, vomiting. <span class="typehead">Urogenital:</span>
<span class="speceff-common">Urinary retention</span>. <span class="typehead">Other:</span> (Rare) <span class="speceff-life">Bone marrow depression</span>. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">antihypertensives</span> may decrease some antihypertensive response; <span class="classification">cns depressants</span>, <b>alcohol,</b>
<span class="classification">hypnotics</span>, <span class="classification">barbiturates</span>, <span class="classification">sedatives</span> potentiate CNS depression; <span class="classification">anticoagulants</span>, <span class="classification">oral</span>, may increase hypoprothrombinemic effect; <b>ethchlorvynol,</b> transient delirium; <b>levodopa,</b>
<span class="classification">sympathomimetics</span> (e.g., <b>epinephrine,</b>
<b>norepinephrine</b>), possibility of sympathetic hyperactivity with hypertension and hyperpyrexia; <span class="classification">mao inhibitors</span>, possibility of severe reactions, toxic psychosis, cardiovascular instability; <b>methylphenidate</b> increases plasma TCA levels; <span class="classification">thyroid drugs</span> may increase possibility of arrhythmias; <b>cimetidine</b> may increase plasma TCA levels. <span class="typehead">Herbal:</span>
<b>Ginkgo</b> may decrease seizure threshold, <b>St. John's wort</b> may cause serotonin syndrome. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI and injection sites. <span class="typehead">Peak:</span> 212 h. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver to active metabolite. <span class="typehead">Elimination:</span> Primarily excreted in urine; enters breast milk. <span class="typehead">Half-Life:</span> 1050 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic effectiveness. It may take 16 wk to reduce attacks when used for migraine prophylaxis.</li>
<li>Monitor for S&amp;S of drowsiness and dizziness (initial stages of therapy); institute measures to prevent falling. Also monitor
            for overdose or suicide ideation in patients who use excessive amounts of alcohol.
         </li>
<li>Lab tests: Baseline and periodic leukocyte and differential counts; renal and hepatic function tests; eye examinations (including
            glaucoma testing); recommended particularly for older adults, adolescents, and patients receiving high doses/prolonged therapy.
         </li>
<li>Monitor BP and pulse rate in patients with preexisting cardiovascular disease. Assess for orthostatic hypotension especially
            in older adults. Withhold drug if there is a rise or fall in systolic BP (by 1020 mm Hg), or a sudden increase or a
            significant change in pulse rate or rhythm. Notify physician.
         </li>
<li>Monitor I&amp;O, including bowel elimination pattern.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Monitor weight; drug may increase appetite or a craving for sweets.</li>
<li>Understand that tolerance/adaptation to anticholinergic actions (see Appendix F) usually develops with maintenance regimen.
            Keep physician informed.
         </li>
<li>Relieve dry mouth by taking frequent sips of water and increasing total fluid intake.</li>
<li>Make position change slowly and in stages to prevent dizziness.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Do not use OTC drugs without consulting physician while on TCA therapy; many preparations contain sympathomimetic amines.</li>
<li>
            							Note: Amitriptyline may turn urine blue-green.
            						
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>